Understanding how antibodies can protect against Brucella infections
Antibody Mediated Immunity Against Brucella
This study is looking at how our immune system responds to a germ called Brucella, which can cause long-lasting infections, and it aims to find ways to make vaccines better at protecting us from this infection by understanding how they work in our bodies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10950094 on NIH RePORTER |
What this research studies
This research investigates the immune response to Brucella, a bacterium that can cause lifelong infections in humans and animals. It aims to understand how antibodies produced by vaccines can alter the metabolism of host tissues to provide protection against this infection. The study will explore the mechanisms by which Brucella evades the immune system and how current vaccines can be improved to enhance their effectiveness. By identifying these processes, the research seeks to contribute to the development of better vaccines for preventing brucellosis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of brucellosis, particularly those in contact with livestock or in regions where the disease is prevalent.
Not a fit: Patients who are not at risk for brucellosis or those who have already been vaccinated against it may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines to prevent brucellosis in humans and animals.
How similar studies have performed: Previous research has shown promise in understanding antibody responses to infectious diseases, but this specific approach to Brucella immunity is relatively novel.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Ateya, Mostafa F — University of Missouri-Columbia
- Study coordinator: Ateya, Mostafa F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.